Other articles

AHA 2023

AHA 2023 | SELECT Trial: Semaglutide in Patients Without Diabetes

AHA 2023 | SELECT Trial: Semaglutide in Patients Without Diabetes

Given the obesity pandemic projected for the year 2035, it is imperative to address this disease as a priority, through well-known hygienic-dietary measures and the use of drugs that have shown promising results. Obesity has been identified as an independent cardiovascular risk factor, even after modifying risk factors associated with diabetes. Semaglutide, a GLP-1 agonist,


Approximately only 2.7% of all diabetic patients with ischemic heart disease in the United States receive optimal treatment consisting in high doses of statins (ACEI/ARAII) or “cardio-stable” antihyperglycemic agents such as SGLT2I and GLP-1RA (three of them). Of the population, 37.4% does not use any medication. Randomization was conducted at the healthcare facility level, rather

ACC 2023 | A DUE-Study (Phase III)

In pulmonary hypertension (PHT), 10 mg macitentan plus 40 mg tadalafil is recommended as a safe combination therapy for newly diagnosed patients or in a significant proportion of patients during follow-up. Using a tablet with a fixed drug combination (FDC) could simplify treatment. The aim of this study was to evaluate the efficacy and safety of macitentan/tadalafil

ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease

Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab on coronary plaque in patients with stable coronary artery disease. The study included 137 patients who underwent coronary angioplasty to the culprit vessel and endovascular imaging (OCT, NIRS/IVUS) to non-obstructive lesions (30%-50%). If their plaque was lipid-rich (defined

ESC 2022


On the 3erd day of the European Cardiology Congress 2022 the INVICTUS study was presented, including 4565 patients with atrial fibrillation secondary to rheumatism driven CAD. The aim of this study was to compare the use of Rivaroxaban vs vitamin K antagonists (VKA) in this populations. Mean age was 50 and most patients were women. 

ESC 2022

ESC 2022 | PERSPECTIVE: Efficacy and Safety of Sacubitril/Valsartan Compared with Valsartan in Cognitive Function of Patients with Cardiac Failure and Preserved Function

About 30 to 80% of patients with heart failure (HF) have some sort of cognitive impairment, with a higher risk of dementia than the general population.  A component of sacubitril/valsartan inhibits neprilysin—an enzyme involved in amyloid-β peptide degradation (Alzheimer’s disease)—, and that could worsen cognitive impairment. The PERSPECTIVE study is the first randomized trial to

ESC 2022

ESC 2022 | SECURE Trial

This study, presented by Dr. Valentin Fuster, focused on the importance of medical treatment compliance, initially showing data from the FOCUS study where the poor compliance observed in patients after an acute myocardial infarction (AMI) event was improved by creating a polypill (aspirin, simvastatin, and ramipril). Based on this, the SECURE randomized study was conducted

ESC 2022


The TIME study, presented by Dr. Thomas MacDonald, is a randomized study of over 21,000 patients with high blood pressure with a follow-up beyond 5 years. As is widely known, high blood pressure is the leading global cause of early death, accounting for nearly 10 million deaths in 2015, of which 4.9 million were caused by

Safety of Acetylcholine in the Cath Lab

The concepts of ischemia with non-obstructive coronary artery disease (INOCA) and myocardial infarction with non-obstructive coronary artery disease (MINOCA) have been established, widely spread, accepted, and included in the different guidelines that support our clinical practice. Among INOCA and MINOCA we find vasospastic angina (VSA) caused by epicardial vessel spasms and angina caused by microvascular

ticagrelor vs. aspirina

Empagliflozin: Better Quality of Life for Patients with Cardiac Failure and Preserved Ejection Fraction

Empagliflozin has shown early and sustained improved quality of life (at least for a year) in patients with cardiac failure and preserved function. Patients with cardiac failure and preserved ejection fraction present a deteriorated quality of life. The EMPEROR-Preserved assessed the efficacy of Empagliflozin in several baseline health status assessments. HRQoL was measured using the

Dieta proinflamatoria y su potencial para desencadenar eventos cardiovasculares

Dietary Guidelines to Improve Cardiovascular Health in 2021

A poor diet is associated with high risk of heart disease, morbidity and mortality.  This scientific document emphasizes the importance of a dietary pattern beyond food or nutrients: it highlights the critical role of early nutrition, presents us with elements to build healthy eating habits and underscores the need to introduce structural changes to achieve